Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production

Experimental Neurology

Volumn 169, Issue 2, 2001, Pages 340-350

  Guidetti, Paolo ^b   Charles, Vinod ^a   Chen, Er Yun ^c   Reddy, P Hemachandra ^a   Kordower, Jeffrey H ^c   Whetsell Jr , William O ^d   Schwarcz, Robert ^b   Tagle, Danilo A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dendrites; Golgi; Huntington's; Mitochondrial; Mouse; Neurodegeneration; Striatum; Transgenic

Indexed keywords

COMPLEMENTARY DNA; HUNTINGTIN; MUTANT PROTEIN;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL LOSS; CONTROLLED STUDY; DENDRITE; DENDRITIC SPINE; GOLGI STAIN; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MITOCHONDRIAL ENERGY TRANSFER; MOUSE; NEOSTRIATUM; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0034994207     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7626     Document Type: Article

References (77)

1. Mammalian succinate dehydrogenase
2. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice
3. HEAT repeats in the Huntington's disease protein
4. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease
5. Complex I defect in muscle from patients with Huntington's disease
6. Are there multiple pathways in the pathogenesis of Huntington's disease?
7. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
8. Mitochondrial dysfunction in neurodegenerative diseases
9. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid
10. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate
11. Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function
12. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: Co-localization at synapses with the GluR2/3 subunit of the AMPA receptor
13. Bioenergetic and oxidative stress in neurodegenerative diseases
14. Regional mitochondrial respiratory activity in Huntington's disease brain
15. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
16. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH
17. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: A combined study using the section-Golgi method and calbindin D28k immunocytochemistry
18. Quantitative histochemistry of cytochrome oxidase in rat brain
19. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease
20. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease
21. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease
22. Exacerbation of NMDA, AMPA, and L-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate
23. Bioenergetics and glutamate excitotoxicity
24. Mitochondrial defect in Huntington's disease caudate nucleus
25. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): Comparison with huntingtin in rat and human
26. Microphotometric analysis of NADH-tetrazolium reductase and alpha-glycerophosphate dehydrogenase in human quadriceps muscle
27. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease
28. Preparation and properties of dihydroubiquinone: Cytochrome c oxidoreductase (complex III)
29. Preparation and properties of NADH: Ubiquinone oxidoreductase (complex I) EC 1.6.5.3
30. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
31. Ultramicrospectrophotomeric determination of cytochrome oxidase for quantitative histochemistry
32. Ionized intracellular calcium concentration predicts excitotoxic neuronal death: Observations with low-affinity fluorescenct calcium indicators
33. Endogenous monocarboxylates sustain hippocampal synaptic function and morphological integrity during energy deprivation
34. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging
35. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy
36. 1H NMR spectroscopy studies of Huntington's disease: Correlations with CAG repeat numbers
37. Antiglutamate therapies in Huntington's disease
38. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
39. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
40. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum
41. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease
42. Staining of human and rat brain Vibratome sections by a new Golgi method
43. Huntington's disease gene (IT15) is widely expressed in human and rat tissues
44. A huntingtin-associated protein enriched in brain with implications for pathology
45. Calcium channel antagonists in the prevention of neurotoxicity
46. Pyruvate and lactate protect striatal neurons against N-methyl-D-aspartate-induced neurotoxicity
47. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease
48. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
49. The expression of Huntingtin-associated protein (HAP1) mRNA in developing, adult and ageing rat CNS: Implications for Huntington's disease neuropathology
50. Evidence for a defect in NADH: Ubiquinone oxidoreductase (complex I) in Huntington's disease
51. Requirement for superoxide in excitotoxic cell death
52. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization
53. Dopaminergic control of kynurenate levels and N-methyl-D-aspartate toxicity in the developing rat striatum
54. Transgenic mice expressing mutated full-length HD cDNA: A paradigm for locomotor changes and selective neuronal loss in Huntington's disease
55. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
56. Recent advances in understanding the pathogenesis of Huntington's disease
57. Clinical correlation of striatal 1H MRS changes in Huntington's disease
58. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
59. Mitochondrial dysfunction in neurodegenerative disorders
60. An increase in lactate output by brain tissue serves to meet the energy needs of glutamate-activated neurons
61. Glia are the main source of lactate utilized by neurons for recovery of function posthypoxia
62. Excitotoxins and Huntington's disease
63. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain
64. Widespread expression of Huntington's disease gene (IT15) protein product
65. Neurons and microvessels of the nodose (vagal sensory) ganglion in young adult and aged rats: Morphometric and enzyme histochemical studies
66. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues
67. Biochemical abnormalities and excitotoxicity in Huntington's disease brain
68. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
69. Metabolic coupling between glia and neurons
70. A simple non-radioactive method for diagnosis of Huntington's disease
71. Neuropathological classification of Huntington's disease
72. New stereological methods for counting neurons
73. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator
74. Cytochrome oxidase: An endogenous metabolic marker for neuronal activity
75. Mechanisms underlying initiation of excitotoxicity associated with metabolic inhibition
76. Hypothermia, metabolic stress, and NMDA-mediated excitotoxicity